ImmunityBio stock news: ANKTIVA expands into papillary-only NMIBC; QUILT-2.005 topline is expected in November, with sales, cash and dilution in focus.

ImmunityBio stock news: ANKTIVA expands into papillary-only NMIBC; QUILT-2.005 topline is expected in November, with sales, cash and dilution in focus.

ImmunityBio stock news: ANKTIVA expands into papillary-only NMIBC; QUILT-2.005 topline is expected in November, with sales, cash and dilution in focus.

Trial record 2022-502526-41-00 in the public EU register, on CTIS.eu

Toronto, Ontario--(Newsfile Corp. - October 26, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical-stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancers, bacteria and viruses, is providing an update on its Phase II Bacillus Calmette-Guérin ("BCG")-Unresponsive Non-Muscle Invasive Bladder Cancer ("NMIBC") Carcinoma In-Situ ("CIS")...

The FDA accepted an NDA for UGN-103 for recurrent low-grade intermediate-risk NMIBC, with a target action date of June 14, 2027.

A trial compared perioperative and oncologic outcomes after 2 different en bloc resection techniques for a single small nonmuscle-invasive bladder tumor.

Peer-reviewed publication reports long-term outcomes from the QUILT-3.032 study supporting durable disease control and bladder preservation CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the publication of long-term data from the Phase 2/3 QUILT-3.032 study (N=100) in the Journal of Urology. The study evaluated ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary disease. Highlights: 71% complete response (CR) rate in patients with BCG-unresponsive NMIBC CIS, with or without papillary disease Median duration of CR of 26.6 months, with responses extending beyond 53 months More than half of responding patients in the FDA-reviewed population maintained complete responses beyond 45 months 84% cystectomy-free survival at 36 months among responders 98.2% disease-specific survival at three years No Grade 4 or Grade 5 treatment-related adverse events reported “The QUILT-3.032 study represents one of the longest follow-up data sets in BCG-unresponsive NMIBC to date, and the results continue to support the durability of ANKTIVA’s unique mechanism of action in generating sustained immune responses,” said Patrick Soon-Shiong, M.D., Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio. “These...

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

Nogapendekin alfa, an IL-15 receptor super agonist, is FDA approved for nonmuscle-invasive bladder cancer (NMIBC) carcinoma in situ.

FDA broadens Anktiva approval to papillary-only bladder cancer, giving ImmunityBio (IBRX) a larger addressable market in BCG-unresponsive NMIBC.

More than 80,000 people a year in the U.S. are diagnosed with bladder cancer. Learn about the screening and treatment options.

On October 14, 2026, the FDA approved nogapendekin alfa inbakicept-pmln (Anktiva) with BCG for BCG-unresponsive non-muscle invasive bladder cancer with high-grade papillary-only tumors. The agency extrapolated from earlier data in patients with carcinoma in situ.

At a recent AACR Special Conference, experts discussed emerging therapeutic options to overcome resistance to Bacillus Calmette-Guérin (BCG).

A trial compared perioperative and oncologic outcomes after 2 different en bloc resection techniques for a single small nonmuscle-invasive bladder tumor.

What ImmunityBio, Inc. changed in their own words, quarter over quarter.

Non-muscle-invasive bladder cancer (NMIBC) is characterized by a high recurrence rate and a substantial long-term surveillance burden. However, current detection and surveillance strategies rely largely on invasive cystoscopy and urine cytology, which are limited by patient discomfort, suboptimal adherence, and insufficient sensitivity, particularly for low-grade disease. This mini review examines the role of liquid biopsy in the detection, risk stratification, and surveillance of NMIBC. It summarizes current evidence on circulating tumor DNA, circulating tumor cells, exosomes and extracellular vesicles, urinary tumor DNA, and DNA methylation and protein biomarkers in blood or urine. For detection, urine-based molecular assays complement cystoscopy and cytology in the noninvasive assessment of patients with suspected bladder cancer. For risk stratification, molecular detection of residual disease and longitudinal biomarker changes help identify patients at increased risk of recurrence or progression. During surveillance, urine-based assays support earlier recurrence detection and, in selected settings, help reduce the frequency of cystoscopy. Overall, liquid biopsy is a promising minimally invasive complement to conventional NMIBC management although technical standardization and prospective clinical validation are required before routine implementation.

A phase 2 open label trial tested intravesical gemcitabine and docetaxel as first-line treatment in patients with high-risk BCG-naïve nonmuscle-invasive bladder cancer.

Intermediate-Risk Non–Muscle-Invasive Bladder Cancer (IR NMIBC) Risk Stratification Model by the International Bladder Cancer Group (IBCG).